Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PT001 + PT005
- Development stage
- Phase 3
- Lead developer
- AstraZeneca
- Modality
- Small Molecules, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
- Administration
- Inhalation
01
Overview
PT001 + PT005 refers to the co-administration of two separate inhaled medications for respiratory disease management. Specifically, it is the combination of glycopyrronium (PT001), a long-acting muscarinic antagonist (LAMA), and formoterol fumarate (PT005), a long-acting beta-2 agonist (LABA). Both are delivered via individual metered dose inhalers. This combination has been studied for its safety and efficacy in patients with moderate to very severe chronic obstructive pulmonary disease (COPD). The rationale is that combining bronchodilators with complementary mechanisms can provide greater improvement in lung function than either agent alone[2][5]. The drugs were developed by Pearl Therapeutics using their proprietary co-suspension technology before the company was acquired by AstraZeneca[5].
- Other names
- GP MDI + FF MDIGlycopyrronium metered dose inhaler + Formoterol Fumarate metered dose inhaler
02
Targets
ADRB2 (β2)CHRM3 (M3)
Beyond the preview
Go deeper on PT001 + PT005.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PT001 + PT005.